Financials
Financial year 2025
ESCAPHARM from Kluisbergen, company number BE0897206151, closed financial year 2025 with a result of € 119,392 after tax. For that financial year ESCAPHARM recorded a gross margin of € 233,538 and equity of € 821,186. Compared with financial year 2024, the result moved from € 105,067 to € 119,392. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 13, 2026.
€ 821,186
▲ 15% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 119,392
▲ 14% vs 2024
Profit after tax over the fiscal year.
€ 32,849
Cash and bank balances on the last day of the fiscal year.
€ 13,621 paid out
11 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
0
Average over the fiscal year, from the social balance sheet.
€ 33,217
▼ 35% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 311,442
▼ 11% vs 2024
€ 33,217 is repaid this year. At this pace the long-term loan is gone in ≈ 9 years.
€ 3,452
▼ 25% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 70,641
▲ 16% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 165,317 | € 199,240 | € 195,640 | € 233,538 | ▲ 19% |
| Profit after taxes | € 81,274 | € 106,410 | € 105,067 | € 119,392 | ▲ 14% |
| Equity | € 536,755 | € 610,348 | € 715,415 | € 821,186 | ▲ 15% |
| Total debts | € 604,264 | € 522,822 | € 593,791 | € 634,504 | ▲ 7% |
| Cash | € 63,231 | € 36,332 | € 32,780 | € 32,849 | |
| Retained profit | € 516,755 | € 590,348 | € 695,415 | € 801,186 | ▲ 15% |
| Dividend | € 1,600 | € 32,816 | € 0 | € 13,621 | |
| Bank debt | € 465,002 | € 386,884 | € 351,005 | € 311,442 | ▼ 11% |
| Balance sheet total | € 1,141,019 | € 1,133,171 | € 1,309,206 | € 1,455,689 | ▲ 11% |
Key figures of ESCAPHARM, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to ESCAPHARM?
What happened at ESCAPHARM in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 119,392 (▲ 14% vs 2024). filed late Source: NBB ↗
- New establishment in Kluisbergen. KBO
- Start of the company according to the CBE. KBO
In short
From € 81,274 profit in 2022 to € 119,392 profit in 2025.
Paid € 173,989 in corporate taxes since 2022.
Best year ever: 2025, with € 119,392 profit.
Paid out € 48,038 in dividends to the owners in total.
Management
Behind ESCAPHARM are Renaud Mertens and Sophie Glorieux. Renaud Mertens is also behind PHARMACIE MERTENS.
Directors
According to the 2025 annual accounts
Sophie Glorieux
Manager
Establishments
Establishment units
Physical locations of this company
Dalstraat 1
9690 Kluisbergen
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0897.206.151
- VAT number
- BE 0897.206.151
- Registered office
- Dalstraat 1, 9690 Kluisbergen
- Names & denominations
- ESCAPHARM
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 8 April 2008
- Peppol
- Active · Active since 2 Dec 2025
- Activities · NACE
Detailhandel in farmaceutische producten